Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Download Data

Edgewise Therapeutics Inc Book Value Per Share 3 year CAGR for the quarter ending March 31, 2024: -68.55%

Edgewise Therapeutics Inc Book Value Per Share 3 year CAGR is -68.55% for the quarter ending March 31, 2024. The book value per share represents the net value of a company allocated to each outstanding share of common stock. It is calculated by dividing shareholders' equity by the weighted average number of shares outstanding. The book value per share provides insight into the intrinsic value of a company's shares and can be used to assess the relative value of a stock compared to its market price. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Edgewise Therapeutics Inc Book Value Per Share for the quarter ending March 31, 2023 was 5.20, a -1.09% change year over year.
Edgewise Therapeutics Inc Book Value Per Share for the quarter ending March 31, 2022 was 5.25, a -97.32% change year over year.
Edgewise Therapeutics Inc Book Value Per Share for the quarter ending March 31, 2021 was 196.42.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends